XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2

License Agreements - Novartis (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended		155 Months Ended
	May 31, 2022	Apr. 30, 2022	Nov. 30, 2009	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
License Agreements
Revenues				$ 823,303	$ 812,987	$ 2,467,935	$ 2,123,414
Product royalty revenues
License Agreements
Revenues				110,293	183,974	350,253	404,440
JAKAFI
License Agreements
Revenues				619,595	547,373	1,761,732	1,542,138
Milestone and contract revenues
License Agreements
Revenues				0	35,000	135,000	45,000
Novartis
License Agreements
Royalties payable				221,700		$ 221,700		$ 221,700	$ 148,100
Novartis | JAKAVI | Minimum
License Agreements
Royalty payments on future global net sales (as a percent)						12.00%
Novartis | JAKAVI | Maximum
License Agreements
Royalty payments on future global net sales (as a percent)						14.00%
Novartis | JAKAFI | UNITED STATES
License Agreements
Royalties payable on net sales				30,300	26,900	$ 81,300	70,600
Novartis | JAKAFI | Non-US
License Agreements
Royalties payable on net sales				85,800	94,700	240,400	242,300
Novartis | Milestone and contract revenues
License Agreements
Revenues				0		60,000
Novartis | TABRECTA PROD SERV | Non-US
License Agreements
Royalties payable on net sales				$ 4,100	$ 2,700	11,200	$ 7,300
Novartis | Development Milestones
License Agreements
Amount recognized and received for the achievement of a predefined milestone								157,000
Novartis | Development Milestones | Maximum
License Agreements
Upfront and immediate milestone payment to be received under license agreement			$ 174,000
Novartis | Regulatory Milestones
License Agreements
Amount recognized and received for the achievement of a predefined milestone								340,000
Novartis | Regulatory Milestones | Maximum
License Agreements
Upfront and immediate milestone payment to be received under license agreement			495,000
Novartis | Regulatory Milestones | TABRECTA
License Agreements
Amount recognized and received for the achievement of a predefined milestone		$ 15,000
Novartis | Regulatory Milestones | JAKAVI
License Agreements
Amount recognized and received for the achievement of a predefined milestone	$ 45,000
Novartis | Commercialization Milestones
License Agreements
Amount recognized and received for the achievement of a predefined milestone								$ 200,000
Novartis | Commercialization Milestones | Maximum
License Agreements
Upfront and immediate milestone payment to be received under license agreement			$ 500,000
Novartis | Development and Regulatory Milestones | Maximum
License Agreements
Upfront and immediate milestone payment to be received under license agreement						$ 75,000

X

- Definition

Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of royalties payable.

+ References

No definition available.

+ Details

Name:	incy_RoyaltiesPayable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_IncreaseDecreaseInRoyaltiesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_JAKAFIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_JakaviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_TABRECTAPRODUCTANDSERVICESMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_TabrectaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: